57 related articles for article (PubMed ID: 25075094)
1. An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.
Umebayashi M; Kiyota A; Koya N; Tanaka H; Onishi H; Katano M; Morisaki T
Anticancer Res; 2014 Aug; 34(8):4509-19. PubMed ID: 25075094
[TBL] [Abstract][Full Text] [Related]
2. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action.
Hirschhaeuser F; Walenta S; Mueller-Klieser W
Cancer Immunol Immunother; 2010 Nov; 59(11):1675-84. PubMed ID: 20652245
[TBL] [Abstract][Full Text] [Related]
4. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
Sebastian M; Passlick B; Friccius-Quecke H; Jäger M; Lindhofer H; Kanniess F; Wiewrodt R; Thiel E; Buhl R; Schmittel A
Cancer Immunol Immunother; 2007 Oct; 56(10):1637-44. PubMed ID: 17410361
[TBL] [Abstract][Full Text] [Related]
5. Catumaxomab: clinical development and future directions.
Linke R; Klein A; Seimetz D
MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
[TBL] [Abstract][Full Text] [Related]
6. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.
Zhang P; Shi B; Gao H; Jiang H; Kong J; Yan J; Pan X; Li K; Zhang P; Yao M; Yang S; Gu J; Wang H; Li Z
Cancer Immunol Immunother; 2014 Feb; 63(2):121-32. PubMed ID: 24177984
[TBL] [Abstract][Full Text] [Related]
7. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.
Palagani V; El Khatib M; Kossatz U; Bozko P; Müller MR; Manns MP; Krech T; Malek NP; Plentz RR
PLoS One; 2012; 7(10):e46514. PubMed ID: 23094026
[TBL] [Abstract][Full Text] [Related]
8. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial.
Riechelmann H; Wiesneth M; Schauwecker P; Reinhardt P; Gronau S; Schmitt A; Schroen C; Atz J; Schmitt M
Cancer Immunol Immunother; 2007 Sep; 56(9):1397-406. PubMed ID: 17273869
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study.
Li YN; Li YY; Wang SX; Ma XY
Curr Med Sci; 2023 Jun; 43(3):539-550. PubMed ID: 37119369
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
Amann M; Friedrich M; Lutterbuese P; Vieser E; Lorenczewski G; Petersen L; Brischwein K; Kufer P; Kischel R; Baeuerle PA; Schlereth B
Cancer Immunol Immunother; 2009 Jan; 58(1):95-109. PubMed ID: 18594818
[TBL] [Abstract][Full Text] [Related]
11. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy.
Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM
MAbs; 2024; 16(1):2322562. PubMed ID: 38445633
[TBL] [Abstract][Full Text] [Related]
12. Efficient carcinoma cell killing by activated polymorphonuclear neutrophils targeted with an Ep-CAMxCD64 (HEA125x197) bispecific antibody.
Schweizer C; Strauss G; Lindner M; Marmé A; Deo YM; Moldenhauer G
Cancer Immunol Immunother; 2002 Dec; 51(11-12):621-9. PubMed ID: 12439607
[TBL] [Abstract][Full Text] [Related]
13. Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study.
Winter A; Zacharowski K; Meybohm P; Schnitzbauer A; Ruf P; Kellermann C; Lindhofer H
BMC Anesthesiol; 2021 Oct; 21(1):261. PubMed ID: 34715784
[TBL] [Abstract][Full Text] [Related]
14. Identification of tumor stem-like cells in admanatimomatous craniopharyngioma and determination of these cells' pathological significance.
Wang CH; Qi ST; Fan J; Pan J; Peng JX; Nie J; Bao Y; Liu YW; Zhang X; Liu Y
J Neurosurg; 2019 Aug; 133(3):664-674. PubMed ID: 31470408
[TBL] [Abstract][Full Text] [Related]
15. A targetable pathway to eliminate TRA-1-60+/TRA-1-81+ chemoresistant cancer cells.
Tan L; Duan X; Mutyala P; Zhou T; Amin S; Zhang T; Herbst B; Askan G; Itkin T; Xiang Z; Michelassi F; Lieberman MD; Iacobuzio-Donahue CA; Leach SD; Evans T; Chen S
J Mol Cell Biol; 2023 Nov; 15(6):. PubMed ID: 37327088
[TBL] [Abstract][Full Text] [Related]
16. Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids.
Harter MF; Recaldin T; Gerard R; Avignon B; Bollen Y; Esposito C; Guja-Jarosz K; Kromer K; Filip A; Aubert J; Schneider A; Bacac M; Bscheider M; Stokar-Regenscheit N; Piscuoglio S; Beumer J; Gjorevski N
Nat Biomed Eng; 2024 Apr; 8(4):345-360. PubMed ID: 38114742
[TBL] [Abstract][Full Text] [Related]
17. Identification and Pharmacological Targeting of Treatment-Resistant, Stem-like Breast Cancer Cells for Combination Therapy.
Worley J; Noh H; You D; Turunen MM; Ding H; Paull E; Griffin AT; Grunn A; Zhang M; Guillan K; Bush EC; Brosius SJ; Hibshoosh H; Mundi PS; Sims P; Dalerba P; Dela Cruz FS; Kung AL; Califano A
bioRxiv; 2024 May; ():. PubMed ID: 38798673
[TBL] [Abstract][Full Text] [Related]
18. Optical image-guided therapy of pancreatic cancer with an ultra-small bispecific protein.
Song W; Hsu JC; Lan X; Cai W
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1560-1563. PubMed ID: 36882578
[No Abstract] [Full Text] [Related]
19. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
[TBL] [Abstract][Full Text] [Related]
20. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells.
Iwahori K; Kakarla S; Velasquez MP; Yu F; Yi Z; Gerken C; Song XT; Gottschalk S
Mol Ther; 2015 Jan; 23(1):171-8. PubMed ID: 25142939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
